Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Advanced Malignant Solid Neoplasm 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × PT-100 dipeptide × Other solid neoplasm × Clear all
NCT04171219 2025-05-16

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
31 enrolled 15 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡